Trial record 1 of 2 for: Hepatocellular Carcinoma GenSpera
Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (G-202-003)
This study is currently recruiting participants.
Verified April 2014 by GenSpera, Inc.
Information provided by (Responsible Party):
First received: January 18, 2013
Last updated: April 11, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|